Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus–Pancreatic Cancer
2024-511271-15-00Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, tiragolumab, bevacizumab, tocilizumab, nab-paclitaxel and 1 more in pancreatic adenocarcinoma (PDAC) (5 arms), sponsored by Roche. Primary endpoint: Objective response. Started Apr 2024; status: completed.
02
Drugs
atezolizumabtiragolumabbevacizumabtocilizumabnab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-511271-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511271-15-00.